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Abstract
Skeletal muscle wasting occurs as a corollary of numerous physiological conditions, including
denervation, immobilization, and aging. The E3 ubiquitin ligases MuRF1 and MAFbx are induced
under nearly all atrophy conditions and are believed to play a key role in protein degradation. Data
in this thesis provides interesting new evidence that MuRF1 may also act as a transcriptional
modulator of atrophy-induced genes or atrogenes. The transcriptional regulation of MuRF1 and
MAFbx were characterized using a reporter gene system and exhibited repressed activity in C2C12
cells overexpressing MuRF1. Furthermore, ectopic expression of the myogenic regulatory factors
(MRFs), MyoD and myogenin, caused significant activation of the MuRF1 and MAFbx reporter
gene constructs, while co-overexpression of MuRF1 with MRFs resulted in reversal of MRF
induction of reporter gene activity. Interestingly, ectopic expression of a catalytically dead MuRF1
RING mutant failed to reverse MRF activation of the reporters, suggesting that ubiquitin ligase
activity may be necessary for MuRF1 transcriptional regulation. To further investigate a potential
mechanism of MuRF1 regulation of MRF activity, Western blot analysis was performed to analyze
MRF protein levels in C2C12 cells overexpressing MuRF1 and MuRF1 RING mutant. Cells with
ectopic MuRF1 or MuRF1 RING mutant showed repressed levels of myogenin. Additionally, cells
overexpressing MuRF1 and MuRF1 RING mutant treated with MG132 showed only a partial
rescue of myogenin protein levels. Finally, chromatin immunoprecipitation was performed to
analyze occupancy of MRFs at the MuRF1 promoter. Overexpression of MRFs resulted in
increased MuRF1 promoter immunoprecipitation (IP) and amplification, while co-overexpression
of MuRF1 with MRFs resulted in a reversal of promoter IP and amplification. These findings
suggest that MuRF1 may regulate MRF transcriptional activity in a non-canonical fashion giving
insight into a potentially new mechanism by which MuRF1 may act to transcriptionally regulate
atrophy-induced gene expression.

vii

Chapter 1: Overview of the Involvement of MuRF1 in Skeletal Muscle Atrophy
Skeletal Muscle Atrophy
Skeletal muscle is a dynamic tissue distinguished by its ability to receive and interpret external
cues and integrate them into a physiological response. The maintenance of this tissue depends
partially on a balance between protein synthesis and degradation that is regulated in response to
the physiological needs of the individual [1]. This balance can often be disrupted due to a myriad
of physiological conditions, which cause the rate of protein degradation to outpace the rate of
protein synthesis. This is characterized as muscle atrophy, a loss of proteins that are essential for
muscle integrity and function [2, 3]. Some conditions that often give rise to skeletal atrophy include
sarcopenia, cancer, corticosteroid use, joint immobilization, disuse, and denervation [1,4]. While
skeletal muscle atrophy and many parts of the atrophy pathway have been well characterized,
numerous elements in the pathway and their roles have been challenging to define. The
characterization and future treatment of neurogenic muscle atrophy depends on research that will
provide a better understanding of the molecular events occurring during this process.

The Ubiquitin Proteasome System and the Role of E3 Ubiquitin Ligases
Protein degradation in muscle atrophy is primarily handled by the 26S ubiquitin proteasome
system (UPS). This system operates through ATP-dependent mechanisms driving the proteasome
to degrade damaged or unneeded proteins by hydrolyzing peptide bonds [5]. Proteins destined for
degradation through the UPS are tagged with a ubiquitin molecule by E3 ubiquitin ligases such as
Muscle RING Finger-1 (MuRF1).
E3 ligase-mediated ubiquitination occurs via a covalent modification of a lysine residue on a target
protein. This process requires a combination of three different enzymes: E1, E2 and E3. The E1
enzyme is responsible for hydrolyzing an ATP molecule and adding adenylate to a ubiquitin
1

molecule [5, 6]. After this step is completed, the adenylated ubiquitin is transferred to a cysteine
residue of the E2, called the ubiquitin-conjugating enzyme [5]. Finally, the E3 ubiquitin ligase
recognizes the protein that needs to undergo degradation and catalytically transfers the ubiquitin
to the target protein (Figure 1) [5]. The E3 enzyme is the most selective component of this system,
as it delegates substrate specificity for the UPS [6].

Figure 1. Schematic of the ubiquitin proteasome system. Protein degradation by the 26S proteasome involves
collaboration of three enzymes; a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (E2) and a
ubiquitin ligase (E3) (Adapted from Molineaux 2012).

MuRF1 as a Marker of Skeletal Muscle Atrophy
Previous research was conducted aiming to identify specific genetic markers expressed at high
levels under atrophy conditions [4]. Two markers of interest were up-regulated in response to
atrophic stimuli: the E3 ubiquitin ligases MuRF1 and Muscle Atrophy F-box (MAFbx) [4]. Bodine
et al. identified MuRF1 and MAFbx in 2001 using differential expression analysis of muscle
isolated from rats that had been subjected to immobilization, denervation, or hind limb suspension.
Interestingly, numerous genes showed altered expression under one or two conditions, but only
2

MuRF1 and MAFbx exhibited induction in response to virtually all conditions of atrophy (Figure
2) [4]. Furthermore, mice lacking MuRF1 or MAFbx expression were resistant to skeletal muscle
atrophy compared to their wild-type littermates, suggesting that MuRF1 and MAFbx are important
mediators of muscle wasting [4, 7, 8, 9]. However, the mechanism by which MuRF1 and MAFbx
regulate atrophy is still not fully understood. In the years since the discovery of these hallmark
indicators of muscle atrophy very few targets of these E3 ubiquitin ligases have been identified.

Figure 2. mRNA expression profiles of MuRF1 and MAFbx in Sprague-Dawley rat gastrocnemius muscle
under muscle atrophy conditions. MuRF1 and MAFbx showed increased expression following limb immobilization,
sciatic nerve denervation, and hind limb suspension by day 1 with maximum expression reached by 3 days. Numbers
represent days post-denervation. (Adapted from Bodine, et al., 2001.)

MuRF1 is an E3 ubiquitin ligase induced under virtually all atrophy conditions, suggesting that it
plays a large role in the destabilization of proteins through the UPS during muscle wasting [4, 10,
11, 12]. MuRF1 has three different functional domains that suggest its potential function(s) in
muscle atrophy (Figure 3). The Really Interesting New Gene (RING) domain is predicted to
perform the catalytic action of MuRF1’s participation in ubiquitination and is needed for E3 ligase
activity [13, 14, 15]. There are also B-box and B-box c-terminal (Bbc) domains that possibly form
additional zinc finger structures that aid in binding to DNA and/or other proteins [15]. The function
of the acidic c-terminus of MuRF1 currently has no known function; however, acidic protein
termini are thought to have a possible role in the subcellular localization of proteins [16].
3

Figure 3. Alignment schematic of the MuRF1 Protein. MuRF1 protein sequences for mouse, rat and human
were downloaded from the Ensembl database (www.ensembl.org). The sequences were then aligned using the
Clustal Omega alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) and shaded using the Boxshade tool
available on the ExPASy Bioinformatics Resource Portal (http://www.expasy.org/).

MuRF1 as a Transcriptional Regulator of Muscle Atrophy
MuRF1 knock-out (KO) mice were created to better understand the targets of MuRF1 under
atrophy conditions. A β-galactosidase-encoding lacZ cassette was inserted within the coding
region of the MuRF1 gene. In theory, MuRF1 wild-type (WT) mice produce functional MuRF1
gene product while KO mice containing the lacZ cassette produce β-galactosidase under control
of the MuRF1 endogenous promoter. Microarray analysis was performed on intact and denervated
gastrocnemius tissue that was isolated from MuRF1 WT and KO mice [13]. MuRF1 gene
expression increased in WT mice following denervation and decreased back to baseline levels by
14 days post-denervation. However, in the MuRF1-null mice, levels of β-galactosidase increased
and remained elevated at 14 days after denervation. The significance of these data lies within the
4

observation that the levels of MuRF1 returned to baseline at two weeks post-denervation, whereas
the levels of β-galactosidase remained elevated at 14 days post-denervation. Both β-galactosidase
and MuRF1 are under the control of the same endogenous MuRF1 promoter, thus it is reasonable
to hypothesize that in wild-type mice MuRF1 may participate in a feedback loop to negatively
regulate its own transcriptional activity (Figure 4) [13].
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Figure 4. Transcriptional regulation of the MuRF1 gene locus is altered in MuRF1-null mice following
denervation. Whole genome expression analysis was conducted on gastrocnemius muscle from (A) wild-type (WT)
and (B) MuRF1-null (KO) mice following 3 days (3D) and 14 days (14D) post-denervation. MuRF1 expression was
elevated at 3 days post-denervation but returned to baseline expression levels by 14 days post-denervation in WT mice
(A). In contrast, β-galactosidase, which is inserted into the MuRF1 locus in the MuRF1-null mice and is under the
control of the endogenous MuRF1 regulatory region, increased at 3 days post-denervation, but remained elevated at
14 days post-denervation in KO mice (B). Each condition was conducted in triplicate and the expression is the average
of three individual mice and error reflects +/- SEM.

Data from the microarray also suggests that MuRF1 might be necessary for the transcriptional
regulation of MAFbx expression under denervation conditions. Expression levels of MAFbx
showed the same trend that was observed with MuRF1: in WT mice MAFbx expression increased
after 3 days of denervation but returned to baseline by 14 days post-denervation. However, in the
MuRF1-KO mice MAFbx expression increased following 3 days of denervation, but also remained
elevated at 14 days post-denervation (Figure 5).
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Figure 5. MAFbx expression is altered in MuRF1-null mice following denervation. Whole genome expression
analysis was conducted on gastrocnemius muscle from (A) wild-type (WT) and (B) MuRF1-null (KO) mice following
3 days (3D) and 14 days (14D) post-denervation. MAFbx expression was elevated at 3 days post-denervation but
returned to baseline expression levels by 14 days post-denervation in WT mice (A). In contrast, MAFbx expression
increased at 3 days post-denervation, but remained elevated at 14 days post-denervation in KO mice (B). Each
condition was conducted in triplicate and the expression is the average of three individual mice and error reflects +/SEM.

As previously mentioned, very few targets of MuRF1 have been identified despite its establishment
as an E3 ubiquitin ligase. Interestingly, outside of this function E3 ligases have been characterized
to be capable of mono-ubiquitination and multi-ubiquitination [17]. These ubiquitination events
do not flag proteins for degradation by the 26S proteasome but instead change the protein’s
structure, cellular localization, function, or serves as a recruitment or binding signal for additional
transcription factors [17]. It is hypothesized that MuRF1 may function to transcriptionally regulate
gene expression in skeletal muscle through ubiquitination events resulting in the ability to
coordinate with myogenic regulatory factors to control gene activity. The ability of MuRF1 to act
as a transcriptional regulator would demonstrate that E3 ligases such as MuRF1 may have a larger
role in atrophy than previously thought.
Myogenic Regulatory Factors
Myogenic regulatory factors (MRFs) are crucial to stimulating and regulating the formation of
muscle tissue (Figure 6). These transcription factors act in conjunction with co-activators or co6

repressors to facilitate transcription of muscle-specific genes. MRFs are characterized by a
standard helix-loop-helix motif, which allows them to bind to the canonical Ebox consensus
sequence of 5’-CANNTG-3’ [18]. These Ebox sequences are found in the promoter regions of
most muscle-specific genes, including MuRF1 and MAFbx, and function as binding sites for
MRFs to modulate transcriptional activity. MyoD and myogenin sequentially and transitorily
associate with promoter regions of a variety of muscle-specific genes. These factors are necessary
for the development of functional skeletal muscle and myogenic commitment, respectively [4, 5,
19].

Figure 6. Model of skeletal muscle myogenesis. The growth of uncommitted mesodermal cells into committed
myotubes depends on cellular signaling from transcription factors including Pax3, Pax7, MyoD1, and Myogenin.
MyoD1 aids in the commitment from satellite cells to un-differentiated muscle myoblast cells whereas myogenin
functions to regulate the formation of differentiated myotubes (Image adapted from Hettmer and Wagers, 2010).

The microarray data demonstrated that MuRF1 also has a role in regulating the transcription of the
myogenic regulatory factors myogenin and MyoD, which are often upregulated in atrophy
conditions [13]. Microarray analysis showed that myogenin and MyoD are significantly
upregulated under denervation. The expression levels of MyoD in MuRF1-KO mice showed
decreased levels at 14 days post-denervation compared to WT mice, whereas expression of
myogenin showed a significant decrease at 3 days post-denervation in MuRF1-KO mice compared
to WT mice (Figure 7). These data together further suggest that MuRF1 may act as a regulator of
7

muscle-specific genes and that myogenin and MyoD may play a role in the atrophy pathway
involving MuRF1.
A

B

Figure 7. MRF expression is altered in MuRF1-null mice following denervation. Whole genome expression
analysis was conducted on gastrocnemius muscle from wild-type (WT) and MuRF1-null (KO) mice following 3 days
(3D) and 14 days (14D) post-denervation. A) MyoD1 and B) myogenin expression increased at both 3 and 14 days
following denervation in wild-type and MuRF1-null mice. Each condition was conducted in triplicate and the
expression is the average of three individual mice and error reflects +/- SEM.

Myogenin is established as an agent of myoblast commitment to differentiation and is required for
cell viability to ensure the proper formation of embryonic myofibers [18, 20, 21, 22]. Interestingly,
it was previously found that the deletion of myogenin resulted in diminished expression of MuRF1
in skeletal muscle and that when these mice experienced neurogenic atrophy (i.e. denervation)
were resistant to muscle wasting [18]. MyoD acts as an early marker of myogenic commitment to
the skeletal muscle lineage [18]. Furthermore, MyoD and myogenin have been characterized as
important regulators of neurogenic atrophy-induced gene expression, including induction of
MuRF1 and MAFbx [10, 16].

8

Myogenic Regulatory Factors as Regulators of MuRF1 and MAFbx
The transcriptional regulation of MuRF1 and MAFbx by MRFs has been investigated in previous
unpublished literature which shows that these transcription factors act as co-activators or corepressors to mediate transcription of muscle-specific genes [23,24].

Again, the proximal

promoters of both MuRF1 and MAFbx contain canonical E-box sequences which are known
binding sites of MRFs (Figure 8, Figure 9) [25]. These conserved E-box sequences have been
characterized to interact with myogenic regulatory factors, specifically including MyoD and
myogenin [26]. It is proposed that these muscle specific factors are working cooperatively with
MuRF1 through conserved Ebox sequences in the promoter region of atrophy-related genes to
suppress or activate expression under neurogenic atrophy conditions.

Figure 8. MAFbx Promoter Alignment. Promoter sequences from mouse, rat, and human MAFbx genes (5000 base
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicated regions are
highlighted in black. Approximate positions of potential MRF transcription factor binding sites are circled in the
alignment: O class, or FoxO, Forkhead binding site (G/A)TAAA(T/C)AA (Ovals); C/EBP TT(G/T)NGNAA
(Diamonds); Muscle specific E box CANNTG (MyoD, etc.) (Large circle).

9

Figure 9. MuRF1 Promoter Alignment. Promoter sequences from mouse, rat, and human MuRF1 genes (5000 base
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicated regions are
highlighted in black. Approximate positions of potential transcription factor binding sites are indicated in the
schematics and highlighted in the alignments: FoxO, (G/A)TAAA(T/C)AA Ovals); C/EBP TT(G/T)NGNAA
(Diamonds); GRE (Square); Muscle specific E box CANNTG (MyoD, etc.) (Large Circles).

Previous Characterization of MuRF1 and Myogenic Regulatory Factors in Transcriptional
Regulation: MuRF1 as a Transcriptional Regulator of MuRF1 and MAFbx
Previous unpublished data showed the role of MuRF1 and the MRFs in the transcriptional
regulation of atrogenes. It was demonstrated that MuRF1 acts, at least in part, by direct and/or
indirect modulation of the MyoD-family of myogenic regulatory factors. The transcriptional
activation of MuRF1 and MAFbx by myogenin and MyoD was confirmed and for the first time it
was demonstrated that MuRF1 cooperates with both MyoD and myogenin to repress MuRF1 and
MAFbx reporter gene expression (Figures 10 and 11, respectively) [23]. These findings provide
support for the microarray data showing that both MAFbx and MuRF1 expression remain elevated
in MuRF1-null mice, suggesting that the MuRF1 gene product is necessary for returning
expression to baseline levels following neurogenic atrophy. These findings also suggest that
10

MuRF1 may act as a modulator of myogenic regulatory factors, although the exact mechanism has
been unclear.
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Figure 10. MuRF1 negatively regulates MRF induction of MuRF1 promoter reporter activity. The MuRF1 500
base pair promoter reporter shows transcriptional repression in response to co-overexpression of MuRF1 and (A)
MyoD or (B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the MuRF1-500bp
promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for
MuRF1 alone or in combination with myogenin or MyoD. The myoblasts were maintained in standard differentiating
culture media. Samples of media were taken at 24 hour intervals and measured for SEAP activity. The samples were
normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in
triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean [23].
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Figure 11. MuRF1 negatively regulates MRF induction of MAFbx promoter reporter activity. The MAFbx 500
base pair promoter reporter shows transcriptional repression in response to co-overexpression of MuRF1 and (A)
MyoD and (B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp
promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for
MuRF1 alone or in combination with MyoD or myogenin. The myoblasts were maintained in standard differentiating
culture media. Samples of media were taken at 24 hour intervals and measured for SEAP activity. The samples were
normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in
triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean [23].
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Overview
MuRF1 and MAFbx are widely accepted as key regulators in skeletal muscle dynamics with roles
in targeting proteins for degradation. Increasing evidence, including data herein, suggests that
MuRF1 functions as a transcriptional regulator of muscle-specific gene. The details of MuRF1 and
its role as a transcriptional regulator of downstream genes has not been thoroughly investigated to
date. The purpose of this research was to build on preliminary data aiming to analyze the
mechanism by which MuRF1 acts as a transcriptional regulator, specifically aiming to characterize
the coordination of MuRF1 and the myogenic regulatory factors, myogenin and MyoD. The data
herein suggests that MuRF1 regulates an array of atrogenes by indirect/direct modification and
interaction with transcription factors such as myogenin and MyoD through the binding of the
canonical Ebox sequences found in the promoter regions of atrophy-induced genes such as MuRF1
and MAFbx. The first aim of this thesis was to investigate the regulation of myogenin and MyoD
by MuRF1. We hypothesize that MuRF1 may be acting as a regulator of myogenin and MyoD by
one of two mechanisms. One possible way this may be occurring is at the post-translational level,
through the 26S proteasome; MuRF1 may be acting as an E3 ligase to ubiquitinate the MRFs and
degrade them through the ubiquitin proteasome system (Figure 12). An alternative mechanism is
that MuRF1 may also be acting through a feedback mechanism that targets the transcriptional
activation of the MRFs (Figure 13). We hypothesize that MuRF1 may be negatively regulating
levels of MyoD and myogenin. A decrease in expression of myogenin and MyoD may cause
differential expression of many muscle specific genes, as they are necessary regulatory factors for
muscle-specific gene expression.

13

Figure 12. Proteasome Model: MuRF1 regulates myogenin and MyoD through the 26S proteasome.
MuRF1 acts as an E3 ligase to poly-ubiquitinate myogenin and MyoD and flag them for degradation by the
ubiquitin proteasome system, down regulating their expression levels and in turn differentially regulating
the transcription of muscle-specific genes in neurogenic atrophy.

A

B

Figure 13. Transcription Model: MuRF1 transcriptionally regulates myogenin and MyoD
expression. MuRF1 may feedback to negatively regulate the transcriptional activity of myogenin or MyoD.
Transcriptional regulation of atrophy-related genes may be occurring through a) negative regulation of
MyoD b) negative regulation of myogenin (possibly through modification of MyoD, a known
transcriptional regulator of myogenin).
14

The second aim of this thesis was to investigate the mechanism by which MuRF1 is coordinating
with the MRFs, specifically investigating the occupancy of the MuRF1 promoter region by
myogenin and MyoD. We hypothesized that the MRFs are occupying the Ebox binding domain of
the MuRF1 promoter at high levels under neurogenic atrophy conditions (i.e. high expression
levels of the MRFs and MuRF1). We also hypothesized that co-overexpressing MuRF1 with the
MRFs would result in MuRF1-medicated reversal of this occupancy, based on previously research
suggesting that MuRF1 is able to transcriptionally regulate its own activity [23]. The data herein
serves to characterize MuRF1 as a transcriptional regulator of atrophy induced genes through the
regulation of myogenin and MyoD in addition to characterizing the molecular mechanism by
which this is occurring.

Chapter 2: Characterization of the Molecular Interaction between MRFs and MuRF1
Experimental Design
Endogenous expression of myogenin and MyoD
The first objective of this research was to effectively identify and characterize the endogenous
expression of both myogenin and MyoD in skeletal muscle cells. C2C12 myoblast cells were plated
and harvested at day 1 (U1) and day 2 (U2) of proliferation and differentiation day 1 (D1),
differentiation day 3 (D3), differentiation day 7 (D7) and differentiation day 9 (D9). These time
points were chosen to be representative of the differentiation process of C2C12 mouse myoblast
cells. The protein was extracted and Western blot analysis was performed to analyze protein levels
over the time course using antibodies against myogenin or MyoD.

15

MuRF1 regulation of myogenin and MyoD
The next objective was to explore if MuRF1 has a role in regulating the expression levels of
myogenin and MyoD and how this is occurring. We hypothesized that this regulation may be
occurring post-translationally, through the ability of MuRF1 to catalytically tag proteins with
ubiquitin molecules, in turn tagging them for degradation by the proteasome. The role of both the
catalytic RING domain, which is responsible for ubiquitinating proteins, and the 26S proteasome
were investigated as follows:
Role of the Catalytic RING Domain
In order to analyze the catalytic activity of MuRF1, site directed mutagenesis was performed to
create a catalytically dead MuRF1 construct. In theory, this MuRF1 RING mutant is unable to
ubiquitinate proteins and flag them for degradation by the 26S proteasome. C2C12 cells were
transfected with ectopic MuRF1 or MuRF1-RING mutant and harvested at differentiation day 2
(D2) and differentiation day 9 (D9). Western blot analysis was performed using antibodies against
myogenin and MyoD.
Role of the 26S Proteasome
To evaluate the role of the 26S proteasome in this regulation, C2C12 cells were transfected with
MuRF1 and then harvested at differentiation day 2 (D2) and differentiation day 9 (D9). Four hours
prior to harvesting the cells, the cells were treated with MG132 [12.5µg/µL], a general 26S
proteasome inhibitor that acts as a peptide aldehyde to effectively block the proteolytic activity of
the proteasome complex. Subsequently, proteins were extracted, purified and Western blot
analysis was performed using antibodies against myogenin and MyoD.
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MuRF1 promoter occupancy by myogenin and MyoD
MuRF1 promoter occupancy by endogenous myogenin and MyoD
To further characterize MuRF1 regulation of the myogenic regulatory factors, Chromatin
Immunoprecipitation (ChIP) was performed to analyze the occupancy of myogenin and MyoD at
the proximal promoter of MuRF1. C2C12 cells were harvested at proliferation day 2 (PD2),
differentiation day 2 (DD2), and differentiation day 9 (DD9). Chromatin immunoprecipitation was
performed using antibodies to isolate myogenin or MyoD. DNA was isolated from the protein
complexes and primers amplifying the conserved Ebox region of the MuRF1 promoter were used
in qPCR, allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence
in the promoter region of MuRF1.
Overexpression of MRFs
An additional experiment was performed to analyze the amount of association between the MuRF1
Ebox and MRFs when myogenin and MyoD were overexpressed in the cell line, which mimics
their expression in neurogenic atrophy. C2C12 cells were transfected to overexpress myogenin or
MyoD and were harvested at 24 hours post-transfection. Chromatin immunoprecipitation was
performed using antibodies to pull down myogenin or MyoD. DNA was isolated from the protein
complexes and primers amplifying the conserved Ebox regions of the MuRF1 promoter were used
in qPCR, allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence
in the promoter region of MuRF1.
Overexpression of MuRF1 + MRFs
The next aim of this research was to assess the ability of MuRF1 to drive down myogenin and/or
MyoD occupancy of the MuRF1 proximal promoter. C2C12 cells overexpressing myogenin or
MyoD +/- MuRF1 were harvested at 24 hours post-transfection, again mimicking expression levels
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that are seen under neurogenic atrophy. Chromatin immunoprecipitation was performed using
antibodies to pull down myogenin or MyoD. DNA was isolated from the protein complexes and
primers amplifying the conserved Ebox regions of the MuRF1 promoter were used in qPCR,
allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence in the
promoter region of MuRF1.
Materials and Methods
Cell Culture
C2C12 mouse myoblast cells were obtained from the American Type Culture Collection (Manassas,
VA). The cells were grown in 10 cm cell culture dishes in 10 mL of media consisting of DMEM
(Life

Technologies, Grand Island, NY) supplemented with 10% FBS (GE Healthcare Hyclone

Laboratories, Logan, UT), Pen/Strep, nonessential amino acids, and gentamycin (Life
Technologies, Grand Island, NY) at 37°C in a 6% CO2 humidified chamber.
Protein Purification and Western Blotting
C2C12 mouse myoblast cells were plated into 10 cm culture dishes at a density of approximately
500,000 cells/mL Cells were harvested over a time course of 12 days, from proliferating myoblasts
to differentiated myotubes. Cells being transfected to ectopically express MuRF1 or MuRF1RING mutant were treated as follows: one hour prior to transfection the media was removed from
the cells and 10 mL of fresh proliferation media was added to each plate. 10µg of total DNA per
plate was transiently transfected using Thermo Scientific Turbofect reagent per the manufacturer’s
protocol. The DNA mixture consisted of a total of 10ug of indicated expressions constructs for
pcDNA3.1-MuRF1 or pcDNA3.1-MuRF1 RING mutant. At approximately 24 hours posttransfection the cells were harvested, centrifuged at 5,000 x g for 5 minutes at 4°C, and stored at 18

80˚C. Protein homogenates were prepared by resuspending the cells in a protein lysis buffer [50
mM Tris, 150 mM NaCl, 50 mM NaF, .5% NP-40] supplemented with a protease inhibitor
cocktail, 1 mM PMSF, 1 mM DTT, 10mM β-glycarophosphate, 1mM Sodium Molybdate,
incubated for 30 minutes on ice and centrifuged at 4°C for five minutes at 18,000 x g. The
homogenate was aliquoted and stored at -80˚C. Protein concentrations were quantified using a
modified Bradford reagent protein assay according to manufacturer’s protocol (Bio-Rad, Hercules,
CA). A total of 150µg of protein was loaded onto an SDS-PAGE gel, separated and then
transferred to a PVDF membrane. The membrane was Ponceau-S stained to check for consistent
protein loading and efficient transfer, washed, and then blocked for one hour in a 5% milk solution
(5% dry milk weight/volume dissolved in .05% Tween-20 in Tris Buffered Saline). The membrane
was washed for fifteen minutes with 1x TTBS and incubated in commercially available primary
antibodies for one hour at room temperature (RT) (MyoD [M-318, rabbit, Santa Cruz
Biotechnology, Inc. or 5.8A, mouse, Santa Cruz Biotechnology, Inc.]; myogenin [F5D, mouse,
Santa Cruz Biotechnology, Inc.]; at a concentration of 1:500 myogenin, MyoD. The membranes
were washed for fifteen minutes, and then incubated in secondary antibody (1:5000) for one hour.
Signal development followed the manufacturer’s protocol for the Pierce ECL Western Blotting
Kit and the blots were imaged on x-ray film.

Site-Directed Mutagenesis of MuRF1-RING Finger Domain
The MuRF1 cDNA sequences for mouse, rat and human were downloaded from the Ensembl
database (www.ensembl.org). The sequences were then aligned using the Clustal Omega
alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). The aligned sequences were used to
identify conserved amino acids for site-directed mutagenesis. Site-directed mutagenesis reactions
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were performed per the manufacture’s protocol (Stratagene, La Jolla, CA). Mutations in the RING
domain of the MuRF1 gene were accomplished by using the following primers: (F) 5ʹCTACAGCAACCGTGAGAAGGCCGACTCCAACCACAACC-3ʹ

and

(R)

5ʹ-

GGTTGTGTTGGAGTCGGCCTTCTCACGGTTGCTGTAG-3ʹ. The resulting MuRF1 clone
was sequenced to confirm the correct mutation was introduced into the gene.

Chromatin Immunoprecipitation
C2C12 cells were plated into 10 cm culture dishes at a density of approximately 500,000 cells/mL
and grown to approximately 75% confluency. One hour prior to transfection the media was
removed from the cells and 10 mL of fresh proliferation media was added to each plate. Total
DNA (10µg per well) was transiently transfected using Thermo Scientific Turbofect reagent per
the manufacturer’s protocol. The DNA mixture consisted of a total of 10ug of indicated expression
constructs for pcDNA3.1-MuRF1, pcDNA3.1-TCF3, pcDNA3.1-TCF12, pcDNA3.1-MyoD, and
pcDNA3.1-Myogenin. Each plate was treated with 1% formaldehyde and incubated at 37˚ for ten
minutes. The cells were treated with .125M glycine, incubated for five minutes, and washed with
PBS containing protease inhibitor cocktail, 10mM β-glycerophosphate, and 0.5 M Na3VO4. Cells
were harvested in 1 ml Collection Buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA), spun
down at 4°C for five minutes at 3,000 x g, and stored at -80˚C. Cells were resuspended in 400µl
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, PIC, 10 mM β-glycerophosphate,
1 mM Na3VO4). The cell lysates were sonicated using a QSonica Ultrasonic Liquid Processor at
the following optimized settings: 50% amplification; pulses of 20 seconds on, 20 seconds off x 30
cycles. The samples underwent centrifugation at full speed for 10 minutes and supernatant was
removed and diluted to 10 mL with ChIP Dilution Solution (0.01% SDS, 1.1% Triton X-100, 1.2
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mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl, PIC, 10 mM β-glycerophosphate, 1 mM
Na3VO4). The chromatin was pre-cleared using 60µl of a slurry of salmon sperm DNA/protein A
agarose (Millipore, Temicula, CA) and rotated for 30 minutes at 4°C, beads were then pelleted by
centrifugation for 2 minutes x 1000g at 4°C. The chromatin was combined with 1 µl of ChIP-grade
antibody (c-myc [9E10, mouse, Santa Cruz Biotechnology, Inc.], myogenin [F5D, mouse, Santa
Cruz Biotechnology, Inc.], MyoD [5.8A, mouse, Santa Cruz Biotechnology]) and incubated
overnight with rotation at 4°C. The samples were combined with 50µl of washed 50% slurry of
Dilution Solution and Protein A/salmon sperm and incubated with tumbling at 4°C for two hours,
followed by centrifugation at 10,000 x g for 2 minutes. The beads were then washed 3x with 1 mL
of each of the following buffers: TSEI (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl, pH 8.0, 150 mM NaCl), TSEII (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl, pH 8.0, 500 mM NaCl), TSEIII (1 mM EDTA, 10 mM Tris-HCl, pH 8.0, 1% NP-40, 1%
sodium deoxycholate, 0.25 M LiCl), Wash Buffer IV (10 mM Tris [pH 8.0], 1 mM EDTA). The
beads were pelleted by centrifugation at 3,000 x g for 2 minutes, followed by addition of 100µl
10% Chelex and incubation at 95°C for ten minutes to reverse DNA-protein crosslinks. After
incubation, the samples were treated with 2µl Proteinase K (Qiagen Sciences, MD) and incubated
at 55°C for 30 minutes, followed by incubation at 95°C for ten minutes. The samples were
centrifuged at full speed for two minutes and the supernatant was collected. The remaining beads
were combined with 100 µl nuclease free water, vortexed, and centrifuged for 2 minutes a full
speed. The resulting supernatant was collected and combined with respective supernatant from the
previous step. The collected DNA aliquots were used for qPCR analysis.
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qPCR
The qPCR reaction was prepared using 2 µL of chromatin from the ChIP assay, 1 µL of forward
primer (500nM), 1 µL of reverse primer (500nM), 5 µL iTaq Universal SYBR Green Supermix
(BioRad) in a total volume of 10 µL. The PCR reaction was cycled at the following parameters:
95˚C for two minutes, 95˚C for thirty seconds, 57˚C for thirty seconds, and 72˚C for one minute
x 40 cycles. The primer sequences used to amplify the MuRF1 promoter were: forward ProEbox
5’-CGGCAGGGCAACAGCGATTT-3’, reverse ProEbox 5’- GTCTTGGTCTGAGGCCCCTC3’. These qPCR reactions were quantified by using a standard curve of amplification of serial
dilutions of the MuRF1 promoter plasmid at 1,000 pM, 100 pM, and 10 pM in concentration. Each
condition was performed in triplicate and standard deviation was calculated.

Bioinformatics Analysis
The nucleotide sequence corresponding to the regulatory regions of mouse, rat, and human MuRF1
and MAFbx promoters were downloaded from the Ensembl database (www.ensembl.org), aligned
using

ClustalW2

alignment

tool

on

the

EMBL

website

(http://www.ebi.ac.uk/Tools/msa/clustalw2/), and shaded using Boxshade analysis of the
ClustalW2 alignment output data (http://www.ch.embnet.org/software/BOX_form.html). The
amino acid sequences for mouse, rat, and human MuRF1 were downloaded from Ensembl and
aligned and shaded as described above.
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Results
Characterization of the ectopic expression of myogenin and MyoD in C2C12 myoblasts
To effectively characterize the endogenous expression of both MyoD and myogenin in skeletal
muscle cells, C2C12 cells and Western blot analysis was performed to analyze protein levels over
the course of differentiation. MyoD showed an increase in expression by day 2 of proliferation
and decreased in expression by day 7 of differentiation (Figure 14). Myogenin increased by day
3 of differentiation and decreased in expressed late in differentiation (Figure 15).

← MyoD
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Figure 14. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts increases in expression late
in proliferation and decreases early in differentiation. C2C12 myoblast cells were plated and harvested at day 1
(U1) and day 2 (U2) of proliferation and day 1 (D1), day 3 (D3), days 7 (D7) and day 9 (D9) after the switch to
differentiation media (2% serum). Western blotting was performed using 150µg of total protein and probed using an
antibody against MyoD.

← myogenin
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Figure 15. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts increases in expression
early in differentiation and decreases late in differentiation. C2C12 myoblast cells were plated and harvested at
day 1 (U1) and day 2 (U2) of proliferation and day 1 (D1), day 3 (D3), days 7 (D7) and day 9 (D9) after the switch to
differentiation media (2% serum). Western blotting was performed using 150µg of total protein and probed using an
antibody against MyoD.

Ectopic expression of MuRF1 and MuRF1-RING mutant downregulates myogenin but not MyoD
in C2C12 myoblasts
To explore if MuRF1 had a role in regulating the expression levels of myogenin and MyoD,
Western blot analysis was performed on C2C12 mouse myoblasts overexpressing MuRF1 or the
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catalytically dead MuRF1 RING mutant at two time points of differentiation. Western blot
analysis showed decreased myogenin expression when MuRF1 or MuRF1-RING mutant were
overexpressed (Figure 16). Western blot analysis probing for MyoD did not show differences in
expression when MuRF1 or MuRF1-RING mutant were overexpressed (Figure 17).

Figure 16. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts is decreased upon
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control expression
plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 2 (D2) and
day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 150µg of total
protein and probed using an antibody against myogenin (biological duplicate shown Figure S1).

← MyoD
Figure 17. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts remains unaltered upon
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control
expression plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day
2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using
150µg of total protein and probed using an antibody against MyoD (biological duplicate shown figure S2).

Inhibition of the 26S proteasome blunts MuRF1-mediated downregulation of myogenin
To evaluate how the role of the 26S proteasome in MuRF1 regulation of myogenin and MyoD,
C2C12 cells overexpressing MuRF1 were treated with MG132 [12.5µg/µL], a general 26S
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proteasome inhibitor [27]. Western blot analysis showed partially increased levels of myogenin
and MyoD in MG132 treated cells, however ectopic MuRF1 was still capable of blunting the
expression levels of myogenin without the function of the 26S proteasome (Figure 18, 19).

Figure 18. Protein expression profile of myogenin (~34kDa) in C2C12 mouse myoblasts is increased upon cell
treatment with MG132 (12.5µg/µL) but is still blunted by ectopic MuRF1. MuRF1-mediated repression of
myogenin expression levels are partially reversed in the presence of MG132 but are not completely rescued from the
blunting effect by ectopic MuRF1. Myoblasts were transfected with control expression plasmid alone (-/-) or an
expression plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch to differentiation media
(2% serum). Western blotting was performed using 150µg of total protein probed using an antibody against myogenin
(biological duplicate shown Figure S3).

← MyoD

Figure 19. Protein expression profile of MyoD (~45kDa) in C2C12 mouse myoblasts is increased upon cell
treatment with MG132 (12.5µg/µL). MyoD expression levels are partially reversed in the presence of MG132, but
no differences are seen upon expression of ectopic MuRF1. Myoblasts were transfected with control expression
plasmid alone (-/-) or an expression plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch
to differentiation media (2% serum). Western blotting was performed using 150µg of total protein probed using an
antibody against MyoD (biological duplicate shown Figure S3).
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Myogenic regulatory factors bind to the proximal promoter regions of MuRF1 and MAFbx
Previously, reporter assays showed that MuRF1 coordinates with myogenin and MyoD to
regulate the promoter activity of atrophy-related genes, such as MuRF1 and MAFbx. Chromatin
immunoprecipitation was performed to analyze the occupancy of endogenous myogenin and
MyoD at the proximal promoter of MuRF1. Endogenous MuRF1 promoter binding appeared to
be highest for myogenin early in differentiation, while MuRF1 promoter binding for MyoD
appeared to be highest early in proliferation and did not show much of a response late in
differentiation (Figure 20).
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Figure 20. Endogenous myogenin and MyoD occupy the MuRF1 Ebox promoter region. The MuRF1 Ebox
promoter is highly occupied by myogenin early in differentiation (DD2) and by MyoD early in proliferation (PD2).
C2C12 myoblast cells were harvested at day 2 post-plating (PD2) and day 2 (DD2) and day 5 (DD5) after the switch
to differentiation media (2% serum). The myoblasts were maintained in standard culture media. ChIP was performed
and DNA-protein complexes were pulled down with antibodies for myogenin (anti-myogenin) and MyoD (antiMyoD). Each qPCR condition was run in triplicate and the error bars represent standard deviation (-/+ S.D.) of the
mean.
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Additionally, the occupancy of the MuRF1 promoter by MRFs was analyzed when myogenin or
MyoD were overexpressed in the cell line. The qPCR analysis of cells overexpressing these
MRFs demonstrated induced occupancy of the MuRF1 promoter region. (Figure 21).
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Figure 21. MRF overexpression induces MuRF1 Ebox promoter occupancy. MuRF1 Ebox promoter was highly
occupied by myogenin in cells overexpressing myogenin, and with MyoD in cells overexpressing MyoD. C2C12
myoblast cells were transfected one day after plating with pcDNA3 expression plasmids for either myogenin or MyoD
and harvested at day 2 post-plating (PD2). The myoblasts were maintained in standard culture media. ChIP was
performed and DNA-protein complexes were pulled down with antibodies for myogenin (anti-myogenin) and MyoD
(anti-MyoD). Each qPCR condition was run in triplicate and the error bars represent standard deviation (-/+ S.D.) of
the mean.

Ectopic expression of MuRF1 reverses MRF occupancy of the MuRF1 promoter region
Overexpressing ectopic MyoD and myogenin seemed to show induced levels of amplification of
the MuRF1 promoter. In order to assess the ability of MuRF1 to drive down myogenin and/or
MyoD occupancy of the MuRF1 proximal promoter cells overexpressing myogenin or MyoD +/MuRF1 were used for ChIP assays as described above. The qPCR analysis showed the
previously observed induction in occupancy of the MuRF1 promoter by myogenin and MyoD.
More importantly, the overexpression of MuRF1 concurrently with either myogenin or MyoD
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resulted in MuRF1-mediated reversal of the MRF occupancy of the MuRF1 proximal promoter
(Figure 22).
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Figure 22. MuRF1-mediated reversal of MRF-induced MuRF1 Ebox promoter occupancy. MuRF1 Ebox
promoter occupancy in cells overexpressing myogenin and MyoD was reversed when MuRF1 was overexpressed.
C2C12 myoblast cells were transfected one day after plating with pcDNA3 expression plasmids for either MuRF1 +/myogenin or MyoD and harvested at day 2 post-plating (PD2). The myoblasts were maintained in standard culture
media. ChIP was performed and DNA-protein complexes were pulled down with antibodies for a) myogenin (antimyogenin) and b) MyoD (anti-MyoD). Each qPCR condition was run in triplicate and the error bars represent
standard deviation (-/+ S.D.) of the mean.

Discussion
MuRF1 has been widely accepted as a marker and key regulator of skeletal muscle atrophy;
however, very few mechanistic targets have been identified to date. Previously, it was found that
MuRF1 expression showed a significant upregulation under denervation conditions, but returned
to baseline levels by 14 days post-denervation in wild-type (WT) animals, while the MuRF1
locus (i.e. β-galactosidase) activity failed to return to baseline levels in MuRF1 knock-out (KO)
animals. Furthermore, microarray analysis showed that myogenic regulatory factors such as
myogenin and MyoD are significantly upregulated in response to denervation. These findings
were among the first to suggest that MuRF1 may act as a transcriptional regulator in muscle
atrophy.
Previous unpublished data from our lab supports the role of MuRF1 as a transcriptional
regulator. MuRF1 and MAFbx reporter plasmid activity was driven down by overexpressing
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MuRF1, suggesting that MuRF1 can transcriptionally regulate itself, MAFbx and other musclespecific genes. Furthermore, when MRFs were overexpressed they induced MuRF1 and MAFbx
promoter activity, while MuRF1 and MRF co-overexpression reversed MRF induction of the
MuRF1 and MAFbx promoters. This was the first study to suggest that MuRF1 may modulate
MRF transcriptional activity. This thesis served to characterize this previously unidentified role
of MuRF1 as a transcriptional regulator in skeletal muscle through its regulation of myogenin
and MyoD. These findings together support the hypothesis that MuRF1 is likely acting through
the transcriptional model to alter the expression of atrophy related genes in muscle cells.

MyoD and myogenin show sequential expression in differentiating myoblasts
As mentioned, the MyoD-family of transcription factors controls muscle cell determination and
differentiation [28]. MyoD has a previously determined role in myogenic determination and
myogenin promotes the commitment of myoblasts to terminal differentiation [18]. Myoblast
fusion is a highly-regulated process and previous studies suggest that MyoD acts as a “pioneer”
to initiate a cascade of events triggering the expression of muscle-specific genes. It has been
hypothesized that these events then allow the sequential binding and activity of myogenin.
Myogenin and MyoD expression in C2C12 muscle myoblasts showed that MyoD increased in
expression early in proliferation and decreased by day 5 of differentiation (Figure 15). Myogenin
expression increases early in differentiation, only after there is an increase in MyoD expression
(Figure 14). This is consistent with a published study showing a similar trend of myogenin and
MyoD expression in C2C12 cell lines over a time course of differentiation [18]. These data
confirmed and supported the characterization of the sequential expression of myogenin and
MyoD in muscle cell differentiation.
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MuRF1 and the catalytically dead MuRF1 RING mutant regulate myogenin but not MyoD
protein expression
Previous unpublished data from reporter assays performed in our lab showed that MuRF1 had an
ability to coordinate with myogenin and MyoD to regulate promoter activity of muscle-specific
genes (Figure 10, Figure 11). Western blot analysis was performed on cells ectopically
overexpressing myogenin and MyoD with and without overexpression of MuRF1 and the
MuRF1-RING mutant. Ectopic expression of MuRF1 blunted the expression of myogenin.
Additionally, the catalytically MuRF1-RING mutant, incapable of ubiquitinating proteins, was
still able to blunt levels of myogenin (Figure 16). These data suggest that MuRF1 can
effectively modulate levels of myogenin, even without a fully functional catalytic domain. These
data were the first to suggest that this regulation was not occurring through catalytic activity of
the RING Finger domain. Interestingly, when Western blot analysis was performed and MyoD
was isolated there was no difference seen in MyoD protein expression upon over-expression of
MuRF1 or the MuRF1-RING mutant (Figure 17). These findings support that MuRF1 is able to
regulate the levels of myogenin, but not MyoD, and that this regulation is through a previously
uncharacterized function by MuRF1.
In previous literature, the E3 ligase MAFbx has been characterized to be an F-box protein with a
role in the ubiquitination of myogenin, which has a MAFbx- recognition motif [29].
Additionally, MAFbx has been characterized to regulate the expression of MyoD by means of
ubiquitination [30]. While we know that MAFbx can regulate the expression of both myogenin
and MyoD, this ability of MuRF1 to do so has not been previously investigated to our
knowledge. Again, these data show that MuRF1 can alter the expression of myogenin but not
MyoD. Previous research has suggested that even though MuRF1 and MAFbx are both
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upregulated in atrophy conditions, the targets of these two E3 ligases may be completely
different [31]. Thus, it is not entirely surprising we see effects on myogenin but not MyoD.

Inhibition of the 26S proteasome does not rescue myogenin protein levels in response to
MuRF1 overexpression
To further investigate the mechanism by which MuRF1 is regulating myogenin, the role of the
26S proteasome was also investigated. Western blotting analysis was performed after treating
cells with MG132, a general 26S proteasome inhibitor. The results showed that while there was
an increase in the amount of myogenin recovered, proteasome inhibition was not enough to fully
rescue myogenin protein levels, as myogenin expression was still blunted when MuRF1 was
overexpressed in the cells (Figure 18). This further confirmed that MuRF1 is not regulating
myogenin through the proteasome system. While we found that MuRF1 was not regulating
myogenin through ubiquitination, these data further elucidate that the hypothesized proteasome
model of MRF regulation is invalid. While it is widely accepted that MuRF1 polyubiquitinates
proteins for degradation through the UPS, these data suggest that MuRF1 may be involved in a
feedback mechanism responsible for transcriptionally regulating atrophy-related genes through
the transcriptional regulation of myogenic regulatory factors such as myogenin.
No effect was seen on MyoD when the catalytic function of the MuRF1 RING domain was
destroyed (Figure 17) or when the proteasome was inactivated (Figure 19). Conversely, MuRF1
was able to down-regulate myogenin levels in both of these cases. Previous literature has
established MyoD as a transcriptional regulator of myogenin [38], therefore we have reason to
believe that MuRF1 may be acting to regulate myogenin by negatively regulating MyoD, thus
resulting in a down-regulating the expression levels of myogenin.
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Endogenous myogenin and MyoD associate with the MuRF1 conserved Ebox sequence
Previous data suggests that MuRF1 regulates myogenin and/or MyoD to suppress MuRF1 and
MAFbx reporter gene activity. To further investigate the mechanistic coordination of MuRF1
with the MRFs, chromatin immunoprecipitation (ChIP) was implemented to examine if the
MuRF1 promoter was being occupied by endogenous levels of either myogenin or MyoD. The
qPCR analysis using primers spanning the MuRF1 Ebox enhancer region suggested that MuRF1
was occupied the most by MyoD early in proliferation and myogenin early in differentiation
(Figure 20).

These results suggest that myogenin and MyoD sequentially associate with Ebox enhancer
sequences in the promoter region of MuRF1 in mouse myoblasts, with MyoD seemingly
occupying the MuRF1 promoter early in proliferation and myogenin early in differentiation. This
is not unexpected, as we know that MyoD is expressed at higher levels earlier in differentiation,
while myogenin is expressed in higher levels later in differentiation. These findings support
expression patterns that were observed with western blot analysis of endogenous MyoD and
myogenin expression in the cell line. This may explain the possible pattern of the induced
association between these MRFs and the MuRF1 Ebox region, especially if MuRF1 is being
induced to regulate muscle-specific genes downstream in the atrophy cascade. Previous literature
has confirmed that histone deacetylases such as Hdac4 upregulate the expression of MRFs which
in turn upregulate MuRF1 and MAFbx, but a direct mechanism for the upregulation of MuRF1
has not been identified to our knowledge [21]. While previous unpublished data has
characterized that atrogenes containing these conserved Ebox regions in the promoter can be
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regulated by MRF overexpression, this thesis provides the first investigation of the mechanism
by which MRFs directly bind to transcriptionally regulate the activity of these E3 ligases.

Co-overexpressing MRFs with MuRF1 shows MuRF1-mediated reversal of MRF-induced
occupancy of the MuRF1 promoter
Myogenin and MyoD were overexpressed in C2C12 cells and ChIP was performed to investigate
the effect of overexpression on MRF occupancy of the MuRF1 promoter in atrophy-like
conditions (i.e. induced MRF levels). It was predicted that high levels of MuRF1 promoter
occupancy when myogenin and MyoD were overexpressed and pulled down, as overexpression
of myogenin and MyoD in reporter assays induced reporter activity of MuRF1 and MAFbx. The
results confirmed that occupancy of the MuRF1promoter was induced when overexpressing
MRFs (Figure 21).
In previous research co-overexpression of MuRF1 with MRFs drove down the MRF-mediated
induction of the MuRF1 promoter in reporter assays. Therefore, it was expected that MuRF1
overexpression would be able to drive down the amplification of MuRF1 promoter association of
both myogenin and MyoD. The results of this experiment confirmed that co-overexpressing
MuRF1 with MRFs resulted in a MuRF1-mediated reversal of myogenin and MyoD occupancy
with the MuRF1 promoter (Figure 22). Additionally, it seems that there is more occupancy of the
MuRF1 promoter by MyoD, which further supports our hypothesis that MuRF1 is regulating
myogenin levels through somehow negatively regulating MyoD.
These data also signified that there is a possible feedback loop occurring in which MuRF1 is
regulating its own transcriptional regulation. This is supported by the microarray analysis
showing that MuRF1 promoter activity did not return to baseline levels in MuRF1 KO mice at 14
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days, which was the first hint at MuRF1 acting as a transcriptional regulator of itself [13]. It also
builds on preliminary research showing that overexpression of MuRF1 down-regulated MuRF1
reporter gene activity. These data strongly suggest that MuRF1 can, in fact, regulate its own
transcriptional activity. It is apparent that myogenin and MyoD are associating at the Ebox
region of the MuRF1 promoter. Additionally, when MuRF1 was overexpressed in C2C12 cells
there were lower levels of MRF occupancy at the MuRF1 promoter. This is the first study that
hints at a mechanism by which MuRF1 acts as a transcriptional regulator indirectly through the
regulation of myogenin, possibly by negatively regulating MyoD.
Transcriptional regulation of atrophy-related genes may be regulated by a potentially intricate set
of feedback mechanisms between E3 ligases and MRFs. For example, myogenin and MyoD are
upregulated in response to atrophy [36] and we know that MyoD must be present to activate
myogenin recruitment [37]. In turn, myogenin acts as a transcriptional regulator of E3 ligases
such as MuRF1 and MAFbx [38]. The data in this thesis supports the characterization of MuRF1
as a transcriptional regulator of not only itself, but other atrophy-related genes such as myogenin
and MyoD. Thus, it is reasonable to propose that MuRF1 participates in a feedback mechanism
that regulates its own expression and regulates the binding of myogenin and MyoD to Ebox
enhancer regions, as they also play a key in the transcriptional regulation of muscle specific
genes.
While this thesis confirms that MuRF1 is not regulating MRFs via the UPS or through the
catalytic activity of the MuRF1 RING Finger domain, MuRF1 may be responsible in regulating a
change in association and/or recruitment of the MRFs and/or their E protein binding partners to
E-box elements within target gene regulatory regions. It is also possible that MyoD1 and
myogenin may recruit MuRF1 to the promoters of target genes and allow for modification of
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other participants in the transcriptional regulatory process. MuRF1 could also be involved in
targeting recruitment of additional transcription factors to the promoters of atrophy-induced
genes, or interact with or recruit additional proteins which themselves associate with the
promoters of muscle-specific genes.
High levels of expression of MuRF1 may play an additional role in preventing these MRFs from
sitting on the Ebox sequence of promoter regions. It is thought that the primary interaction of the
MRFs is to dimerize before they associate with a promoter region [39]. These transcription
factors must either homodimerize or heterodimerize with factors such as E proteins to form a
functional dimer that can sit down on the consensus E-box sequences [39, 40]. MuRF1 may have
a role in regulating MyoD or the binding partners of MyoD, thus preventing them from
dimerizing with their appropriate binding partners to effectively transcriptionally regulate
myogenin. This may ultimately sequester these MRFs from effectively sitting down on
conserved Ebox promoter regions.
We propose a novel function of MuRF1 in targeting downstream atrogenes through
transcriptional regulation, mainly through the negative regulation of myogenin and MyoD at the
conserved Ebox sequences in the promoter regions of muscle-specific genes. Further research on
how MuRF1 is mechanistically modulating MRFs to ultimately transcriptionally regulate
atrogenes will need be conducted, but this study serves as the first evidence of the coordination
of MuRF1 and MRFs in the transcriptional regulation of muscle specific genes during skeletal
muscle atrophy.
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Conclusions
In summary, the data herein elucidates a previously uncharacterized function for MuRF1 as a
transcriptional regulator of atrogenes through the transcriptional regulation of the myogenic
regulatory factors, myogenin and MyoD. MuRF1 is largely recognized in literature as an E3
ubiquitin ligase that is expressed at high levels under virtually all atrophy conditions; however,
these data suggest that MuRF1 is also working outside of the ubiquitin proteasome system to
transcriptionally regulate itself and other muscle specific genes through a feedback loop that
controls MRF-mediated regulation of gene expression in muscle atrophy.
Previously, it was shown that MuRF1 can regulate the promoter activity of itself by mediating
the activity of MyoD and myogenin. We have now determined that MuRF1 modulates myogenin
and MyoD occupation of the conserved Ebox sequence found in the promoter region of MuRF1.
Interestingly, when MuRF1 was overexpressed concurrently with myogenin or MyoD we saw a
decrease in the occupancy of the MRFs at the Ebox promoter region of MuRF1. Western blot
analysis also indicated that MuRF1 regulates myogenin but not MyoD, suggesting that it has
specific downstream targets that differ from other E3 ligases such as MAFbx. Furthermore,
MuRF1 was still capable of decreasing the amount of myogenin protein expression without both
the catalytic RING domain and without the function of the 26S proteasome. This refutes that
MuRF1 is regulating the MRFs through its previously characterized function of an E3 ligase
working through the UPS (Figure 12) and supports our previously mentioned transcription model
(Figure 13); MuRF1 may be acting as a transcriptional regulator of myogenin and other atrophyrelated genes, possibly via the negative regulation of MyoD.
Additional research is still needed to further characterize the exact mechanism by which MuRF1
is acting as a transcriptional regulator. The involvement of E proteins, which are the ubiquitously
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expressed binding partners of myogenin and MyoD, should also be investigated to better
understand how MuRF1 can modulate the MRFs. MRF occupancy of the MuRF1 promoter
should also be evaluated in response to ectopic expression of MuRF1 mutants, as well as siRNA
knockdown of MuRF1. The preferential regulation of myogenin over MyoD should also be
further investigated, as this could elucidate the function of MuRF1 in regulating transcriptional
activity of atrophy-related genes. Finally, MuRF1 might also be investigated beyond its
capabilities as a transcriptional regulator; the nature of skeletal muscle atrophy is intricate and
regulation occurs on many levels, therefore the analysis of MuRF1 post-transcriptionally would
also likely yield pertinent information regarding the molecular mechanisms of skeletal muscle
atrophy.
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Supplemental Figures

Figure S1. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts is decreased upon
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control expression
plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 2 (D2) and
day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 150µg of total
protein and probed using an antibody against myogenin.

← MyoD
Figure S2. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts remains unaltered upon
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control
expression plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day
2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using
150µg of total protein and probed using an antibody against MyoD.
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Figure S3. Protein expression profile of myogenin (~34kDa) and MyoD (~45 kDa) in C2C12 mouse myoblasts
treated with MG132 (12.5µg/µL) and ectopically expressing MuRF1 or the catalytically dead MuRF1 RING
mutant. MuRF1-mediated repression of myogenin expression levels are partially reversed in the presence of MG132
but are not completely rescued from the blunting effect by ectopic MuRF1 or MuRF1 RING mutant. MyoD expression
levels are partially reversed in the presence of MG132, but no differences are seen upon expression of ectopic MuRF1
or MuRF1 RING mutant. Myoblasts were transfected with control expression plasmid alone (-/-) or an expression
plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum).
Western blotting was performed using 150µg of total protein probed using an antibody against myogenin or MyoD.
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